Efient is a new antiplatelet agent that was granted marketing authorization by the European Commission on February 25, 2009, for the reduction of atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Efient will be co-promoted in the UK by Daiichi Sankyo and Eli Lilly.
The approval of Efient in the UK was based on the Triton trial. In this study, Efient compared with clopidogrel bisulfate provided a 19% reduction in the primary composite endpoint of cardiovascular disease, myocardial infarction, or stroke (ARR – 2.2%; 11.5% versus 9.4%).
Efient was discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries and co-developed by Daiichi Sankyo and Eli Lilly and Company.